Last edited by Nikonris
Sunday, May 10, 2020 | History

3 edition of Nephrotoxicity of Clinically Relevant Drugs (Mineral and Electrolyte Metabolism, Vol 20, No 4) found in the catalog.

Nephrotoxicity of Clinically Relevant Drugs (Mineral and Electrolyte Metabolism, Vol 20, No 4)

William M. Bennett

Nephrotoxicity of Clinically Relevant Drugs (Mineral and Electrolyte Metabolism, Vol 20, No 4)

by William M. Bennett

  • 295 Want to read
  • 5 Currently reading

Published by S. Karger AG (Switzerland) .
Written in English

    Subjects:
  • Medical toxicology,
  • Renal medicine,
  • Endocrinology & Metabolism,
  • Medical / Nursing,
  • Science/Mathematics

  • The Physical Object
    FormatPaperback
    Number of Pages76
    ID Numbers
    Open LibraryOL12930469M
    ISBN 103805560915
    ISBN 109783805560917
    OCLC/WorldCa35529557

    Nephrotoxicity is a significant treatment complication that has limited the clinical utility of cyclosporine. A number of recent studies have examined novel pathways and potential therapeutic targets in the prevention of cyclosporine nephrotoxicity.   Drug use and nephrotoxicity in the intensive care unit. This paper will review these clinically relevant aspects of drug-induced nephrotoxicity for the clinical nephrologist.

    Nephrotoxic drugs are pharmacotherapies that can lead to a decline in renal function. The drug may need to be discontinued, or the dosing reduced when this happens. Common Nephrotoxic drugs.   Comprehensive and clinically relevant, the 3rd Edition of Critical Care Nephrology provides authoritative coverage of the latest advances in critical care procedures for patients with renal diseases or disorders. Using common guidelines and standardized approaches to critically ill patients, this multidisciplinary reference facilitates better communication among all physicians who care for Format: Book.

    CIS affects the S3 segment of the proximal tubule and nephrotoxicity is generally marked by increased serum creatinine and a decreased GFR, along with hypomagnesaemia and hypokalae63– Risk factors include cumulative dose, dehydration, concomitant use of other nephrotoxic drugs and by: 9. Addressing safety concerns such as drug-induced kidney injury (DIKI) early in the drug pharmaceutical development process ensures both patient safety and efficient clinical development. We describe a unique adjunct to standard safety assessment wherein the metabolite profile of treated animals is compared with the MetaMap Tox metabolomics database in order to predict the potential for a wide Cited by:


Share this book
You might also like
An original and authentic record of the life and deeds of General Ulysses S. Grant.

An original and authentic record of the life and deeds of General Ulysses S. Grant.

Science for the people

Science for the people

Wolf literature references

Wolf literature references

modern course in salesmanship

modern course in salesmanship

An organizational approach to correctional effectiveness

An organizational approach to correctional effectiveness

All around the town

All around the town

Coos Bay to Interstate-5

Coos Bay to Interstate-5

Geodesy.

Geodesy.

Some trannie that!

Some trannie that!

Hydrogeology, chemical quality, and availability of ground water in the Upper Floridan Aquifer, Albany area, Georgia

Hydrogeology, chemical quality, and availability of ground water in the Upper Floridan Aquifer, Albany area, Georgia

Transparency and integrity in corporate monitoring

Transparency and integrity in corporate monitoring

facts about--

facts about--

East comes west

East comes west

The Xs and Os of Turners Syndrome

The Xs and Os of Turners Syndrome

boomerang book of Australian poetry.

boomerang book of Australian poetry.

Nephrotoxicity of Clinically Relevant Drugs (Mineral and Electrolyte Metabolism, Vol 20, No 4) by William M. Bennett Download PDF EPUB FB2

Nephrotoxicity of Clinically Relevant Drugs (Mineral and Electrolyte Metabolism, No 4): Medicine & Health Science Books @   Drug-induced nephrotoxicity in adults is approximately 14%–26% in prospective cohort studies of AKI, whereas 16% of hospitalized AKI is due to drugs in the pediatric population (1 – 4).

Drug-induced nephrotoxicity is more common in hospitalized patients, Cited by: The kidneys normally receive 20% of the cardiac output. Drugs are filtered and/or secreted and then progressively concentrated in the urine.

Therefore, these organs are especially vulnerable to the toxic effects of many drugs, including chemotherapy toxicity is often a dose-limiting adverse effect of chemotherapy. Chemotherapy agents can affect the microvasculature, the glomerulus. Nephrotoxicity is the major adverse effect of the valuable immunosuppressive drug cyclosporine.

The pharmacology and pharmacokinetic behavior of cyclosporine is complex; clinically relevant considerations, including drug interactions, are covered in this by: 2.

This page includes the following topics and synonyms: Nephrotoxic Drug, Nephrotoxin, Drug-induced Nephrotoxicity, Medication Causes of Acute Kidney Injury, Medication Causes of Nephrotoxicity of Clinically Relevant Drugs book Tubular Necrosis, Medication Causes of Interstitial Nephritis, Medication Causes of Glomerulonephritis, Medication Causes of Prerenal Failure, Medication Causes of Postrenal Failure, Toxic Nephropathy, Drug.

Aminoglycoside antibiotics, radiocontrast media, conventional nonselective nonsteroidal anti-inflammatory drugs, and selective cyclooxygenase-2 inhibitors, amphotericin B, and angiotensin-converting enzyme inhibitors have been frequently implicated.

This chapter reviews the clinical presentation and basic mechanisms of drug-induced by: Nephrotoxic medications as triggers and risk factors for AKI: it is perhaps a misnomer to consider a fall in GFR as a ‘side effect’ as these drugs act within the kidney in exactly the way they are designed to: they block intra-renal production (ACEI) or action (ARB) of angiotensin II.

when the primary clinical problem associated. In book: Drug-Induced Mitochondrial Dysfunction (pp - ) The list of nephrotoxic drugs is long.

We therefore investigated the effects of clinically relevant NRTI and PI combinations. Patients at highest risk of drug-induced nephrotoxicity are those with one or more of the following: age older than 60 years, baseline renal insufficiency (e.g., GFR Cited by: There are several established clinical risk factors for nephrotoxicity in cancer patients, including renal drug handling, direct tumor impact on kidney structure, true or effective volume.

various drugs also leads to the development of various types of kidney disorders like acute and chronic renal failure. The nephrotoxic effect is usually more in patients who have the history of renal impairments. Nephrotoxicity occurs when the renal blood is exposed to a nephrotoxic drug or toxin that causes damage to the Size: KB.

Drug-induced nephrotoxicity remains a major problem in the clinical setting, where the use of nephrotoxic drugs is often unavoidable.

This leads frequently to acute kidney injury, and current problems are discussed. One strategy to avoid such problems would be the development of drugs with decreased nephrotoxic by: Written by a leading researcher in the field, Transporters in Drug Discovery and Development provides a comprehensive and practical guide to drug transporter families that are the most important for drug discovery and development.

It covers: an overview of transporter families and organ distribution; clinical relevant drug-drug interaction. In selecting drugs effort fosters, should facilitate the advancement of for inclusions in this book the editors were guided by sound science. both frequency and current knowledge.

For occupa­ Our approach to the field of nephrotoxicity is from tionall environmental exposures similar guidelines the perspective of a book which will be of value. The kidney is a major target for drug-induced toxicity.

Drug-induced nephrotoxicity remains a major problem in the clinical setting, where the use of nephrotoxic drugs is often unavoidable. This leads frequently to acute kidney injury, and current problems are discussed. One strategy to avoid such problems would be the development of drugs with decreased nephrotoxic by: How to prevent, recognize, and treat drug-induced nephrotoxicity Article Literature Review (PDF Available) in Cleveland Clinic Journal of Medicine 69(4),passim May Abstract.

The majority of drugs commonly used in clinical practice have a low incidence of renal toxicity. In assessing the frequency of nephrotoxicity, it is clear that most renal injury tends to cluster around certain patients and specific clinical by: 1.

NNRTIs are predominantly metabolized by CYP enzyme system, including 3A4, 2D6, 2B6, 2C9 and 2C19 isoenzymes. Also they act as inhibitors or inducers of these enzymes, further complicating the potential for significant interactions with other by: The nephrotoxic effect of most drugs is more profound in patients already suffering from kidney failure.

About 20% of nephrotoxicity is induced and caused by drugs; this percentage is augmented in the elderly due to an increase in the life span and poly-medications.

Nephrotoxicity is toxicity in the is a poisonous effect of some substances, both toxic chemicals and medications, on kidney function.

There are various forms, and some drugs may affect kidney function in more than one way. Nephrotoxins are substances displaying nephrotoxicity. Nephrotoxicity should not be confused with the fact that some medications are predominantly excreted by.

This review summarizes the nephrotoxic potential of chemotherapy agents, old and new, as well as the different factors that contribute to kidney injury.

Provided for each class of chemotherapy agent is the associated kidney lesion and a brief discussion of clinical manifestation, mechanism of action, and possible treatment when : Anthony Nicolaysen.Of particular importance in drug development is the assessment of a new medicine's potential for causing drug-induced kidney injury (DIKI) (or drug-induced nephrotoxicity, DIN).

Not only is the kidney a vital organ, but due to its elimination of the majority of drugs and their metabolites, and its concentration of these in the process of filtration, it is particularly sensitive to chemical by: A series of clinically used drugs -- cisplatin, doxorubicin, PAP, and colchicine -- with known and varying nephrotoxicity in vivo were chosen for evaluation.

Cisplatin is a potent, platinum-based drug that kills cancer cells through crosslinking DNA, and a common chemotherapeutic agent used to treat several forms for cancers, including Cited by: